Trial Profile
GLYCEMIC CONTROL AND TREATMENT SATISFACTION USING FINESSE VERSUS PEN FOR INITIATING BOLUS INSULIN DOSING IN TYPE 2 DIABETES MELLITUS PATIENTS NOT ACHIEVING GLYCEMIC TARGETS ON BASAL INSULIN WITH/WITHOUT ANTI-HYPERGLYCEMIC AGENTS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Calibra Medical; Medpace
- 06 Nov 2018 Status changed from recruiting to completed.
- 04 Dec 2017 This trial has been completed in Germany, according to European Clinical Trials Database
- 25 Jan 2016 New trial record